2024-514919-10-00Active, not recruitingPhase 4
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic head and neck cancer patients
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic patients with head and neck squamous cell carcinoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Nov 2024
Brief summary (registry, in English)
To investigate if the use of weekly low dose cisplatin increases compliance to the planned chemotherapy scheme in LA-HNSCC patients with low SMM to a level of compliance to three-weekly high dose cisplatin of patients without low SMM.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- First submitted
- 9 Oct 2024
- Start date
- 24 Jan 2022
- Lead sponsor
- Universitair Medisch Centrum Utrecht
- Diseases
- Head and neck cancer
- EU CT number
- 2024-514919-10-00
- EudraCT number
- 2021-002634-16
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 160
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- mentally disabled or patients with significantly altered mental status that would prohibit understanding and giving informed consent; - a history of bilateral lymph node dissection in the neck and no available (PET-)CT scan of the third lumbar vertebra; - an absolute contraindication for cisplatin as defined by the treating physician, including relevant pre-existing kidney insufficiency, clinically apparent vascular disease (for example claudicatio intermittens), clinically relevant perceptive deafness, serious neuropathy and poor performance score;
Who the study is looking for
- considered, eligible and planned for primary cisplatin CRT by treating physician; - eighteen years of age or older; - sufficient understanding of Dutch and medical consequences to give informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Noordwest Ziekenhuisgroep Stichting | Alkmaar | Netherlands | Active, not recruiting |
| Amsterdam UMC Stichting | Amsterdam | Netherlands | Active, not recruiting |
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Amsterdam | Netherlands | Active, not recruiting |
| Leids Universitair Medisch Centrum (LUMC) | Leiden | Netherlands | Active, not recruiting |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.